Vardenafil Troche

Overview of Vardenafil Troche

Dosage Strength

20 mg

General Information

Vardenafil is a member of the medication class known as phosphodiesterase type 5 (PDE5) inhibitors, which is frequently used to treat erectile dysfunction (ED). Like sildenafil and tadalafil, it is a selective phosphodiesterase (PDE) type 5 inhibitor. Unlike several ED medications, this family of medicines does not suppress prostaglandins (e.g., alprostadil). PDE5 is more specifically targeted by vardenafil and tadalafil than PDE6, which is found in the retina. Less visual side effects like those experienced by people using sildenafil as a result. Vardenafil may have the advantage of reaching its peak plasma concentration earlier than sildenafil and tadalafil, which could lead to a quicker onset of effect. 80 percent of the males who participated in an analysis of 580 patients reported having better erections, and the ability to finish a sexual encounter with ejaculation also improved. It has also been shown to be effective in treating diabetics and men who have undergone radical prostatectomy. Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitor) are regarded as first-line therapy for treating ED. 1 In August 2003, the FDA authorized the erectile dysfunction drug vardenafil. The FDA authorized an orally disintegrating tablet in June 2010.

References

1.Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2.Levitra (vardenafil) package insert. Kenilworth, NJ: Schering-Plough; 2007 Mar.
3.Staxyn (vardenafil orally disintegrating tablets) package insert. Whitehouse Station, NJ: Schering-Plough; 2010 Jun.
4.Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am C
5.Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.
6.Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
7.van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.
8.Benoit SR, Mendelsohn AB, Nourjah P, et al. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12(4):363-368.
9.Koide T, Ozeki K, Kaihara S, et al. Etiology of QT prolongation and T wave changes in chronic alcoholism. Jpn Heart J 1981;22:151-166.
10.Galli-Tsinopoulou A, Chatzidimitriou A, Kyrgios I, et al. Children and adolescents with type 1 diabetes mellitus have a sixfold greater risk for prolonged QTc interval. J Pediatr Endocrinol Metab 2014;27:237-243.
11.Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin N Am 2007;34:631-642.
12.Bortolotti M, Mari C, Giovannini M, et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci 2001;46:2301-2306.
13.Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005;25:9-13.
14.Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol 2005;123(3):399-400.
15.Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005;123(3):400-1.
16.Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye 2005;19(6):715-7.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.

Get Started For $99 Initial Provider Consult